Answers are grounded in this paper and cite their sources.
PURPOSE: Type 2 diabetes (T2D) has been associated with an increased risk of colorectal cancer (CRC) and poorer survival outcomes. However, the role of tumor immune status in influencing these relationships remains unclear. METHODS: ) immune infiltration on the basis of standard cutoffs (25% and 70%). Multivariable logistic regression estimated CRC risk, whereas time-dependent Cox regression evaluated survival outcomes. Primary end points included CRC-specific survival and disease-free survival (DFS). RESULTS: CRC subtypes. Patients with T2D showed inferior overall and non-cancer-related survival regardless of immune subtypes. CONCLUSION: T2D disproportionately affects CRC risk and survival in tumors with low immune infiltration, suggesting a continuum of T2D's impact from tumorigenesis to prognosis, through systemic and tumor-specific immune modulation. These findings highlight the need for precision prevention strategies integrating metabolic and immune-based interventions to mitigate CRC burden in patients with T2D.
No takes yet. Share an insight, caveat, or question.
Wankhede et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: